Generex receives patent in Mexico for aerosol drug delivery

By E. Janene Geiss

Philadelphia, June 9 - Generex Biotechnology Corp. said Friday that it has been granted a patent by the Mexican Institute of Industrial Property titled Aerosol Formulations for Buccal and Pulmonary Application.

The patent, an extant U.S. patent registered by the company, relates to an improved delivery system for the administration of large-molecule pharmaceuticals, which may be administered by means of an aerosol into the mouth for buccal or pulmonary application, according to a company news release.

"This patent is one of three that have been granted to the company in Mexico over the past three months in respect of its buccal drug delivery technologies," Rose Perri, chief operating officer, said in the release.

The company said it is preparing regulatory approvals for its flagship oral insulin product, Generex Oral-lyn.

Generex said it holds 73 patents worldwide, 19 of which are U.S. patents, and has 57 patent applications pending in various jurisdictions.

Generex is a Toronto biopharmaceutical company that develops drug delivery systems and technologies.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.